JP2008507550A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507550A5
JP2008507550A5 JP2007522782A JP2007522782A JP2008507550A5 JP 2008507550 A5 JP2008507550 A5 JP 2008507550A5 JP 2007522782 A JP2007522782 A JP 2007522782A JP 2007522782 A JP2007522782 A JP 2007522782A JP 2008507550 A5 JP2008507550 A5 JP 2008507550A5
Authority
JP
Japan
Prior art keywords
disorder
azabicyclo
hexane
racemic
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007522782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025974 external-priority patent/WO2006012474A1/en
Publication of JP2008507550A publication Critical patent/JP2008507550A/ja
Publication of JP2008507550A5 publication Critical patent/JP2008507550A5/ja
Pending legal-status Critical Current

Links

JP2007522782A 2004-07-22 2005-07-21 神経系障害及び状態の処置方法 Pending JP2008507550A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59020304P 2004-07-22 2004-07-22
PCT/US2005/025974 WO2006012474A1 (en) 2004-07-22 2005-07-21 Method for treating nervous system disorders and conditions

Publications (2)

Publication Number Publication Date
JP2008507550A JP2008507550A (ja) 2008-03-13
JP2008507550A5 true JP2008507550A5 (enExample) 2008-08-21

Family

ID=35149631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007522782A Pending JP2008507550A (ja) 2004-07-22 2005-07-21 神経系障害及び状態の処置方法

Country Status (14)

Country Link
US (2) US20060020015A1 (enExample)
EP (1) EP1773320A1 (enExample)
JP (1) JP2008507550A (enExample)
KR (1) KR20070034126A (enExample)
CN (1) CN101410106A (enExample)
AU (1) AU2005266994A1 (enExample)
BR (1) BRPI0512186A (enExample)
CA (1) CA2574310A1 (enExample)
IL (1) IL180731A0 (enExample)
MX (1) MX2007000853A (enExample)
NO (1) NO20070912L (enExample)
RU (1) RU2007102292A (enExample)
WO (1) WO2006012474A1 (enExample)
ZA (1) ZA200700578B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
JP2008507552A (ja) * 2004-07-22 2008-03-13 ワイス 神経系障害および状態の治療方法
KR20070045278A (ko) * 2004-07-22 2007-05-02 와이어쓰 신경계 질환 및 장애의 치료 방법
US8000005B2 (en) * 2006-03-31 2011-08-16 Prysm, Inc. Multilayered fluorescent screens for scanning beam display systems
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3166571A (en) * 1962-06-06 1965-01-19 American Cyanamid Co 1-phenyl-1, 2-cyclopropane dicarboximides
US3344026A (en) * 1966-05-16 1967-09-26 American Cyanamid Co Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression
US3892772A (en) * 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
GR72713B (enExample) * 1976-09-15 1983-12-01 American Cyanamid Co
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3378208D1 (en) * 1982-12-21 1988-11-17 Ciba Geigy Ag Substituted azabicycloalkanes, their use, pharmaceutical preparations containing these compounds and process for preparing these compounds
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DE19919336A1 (de) * 1999-04-27 2000-11-16 Consortium Elektrochem Ind Verfahren zur Ringspaltung von Thiazolidinderivaten
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
ATE369330T1 (de) * 2001-02-12 2007-08-15 Wyeth Corp O-desmethyl-venlafaxine succinat salz
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
WO2003050075A1 (en) * 2001-12-05 2003-06-19 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
KR20070045278A (ko) * 2004-07-22 2007-05-02 와이어쓰 신경계 질환 및 장애의 치료 방법

Similar Documents

Publication Publication Date Title
Thase Antidepressant treatment of the depressed patient with insomnia
Monti et al. Sleep disturbance in schizophrenia
JP2019031502A5 (enExample)
TW201011007A (en) Treatment for neurological and mental disorders
JP2023509720A (ja) 認知障害の予防及び療法
JP2020514313A5 (enExample)
MX2010002890A (es) 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas.
TW201642853A (zh) 用於治療肝功能之損傷及／或腎功能之損傷個體疼痛之西博帕多（Ｃｅｂｒａｎｏｐａｄｏｌ）
CN119095595A (zh) 用于治疗睡眠紊乱的5-meo-dmt
JP2008507550A5 (enExample)
JP2005508872A5 (enExample)
CN119278036A (zh) 用于治疗睡眠紊乱的5-MeO-DMT
RU2007102292A (ru) Способ лечения расстройств и заболеваний нервной системы
RU2007102291A (ru) Способ лечения расстройств и заболеваний нервной системы
Kamal et al. The effect of sleep hygiene and relaxation Benson on improving the quality of sleep among health failure patients: A literature review
RU2007102290A (ru) Способ лечения нарушений и заболеваний нервной системы
JPWO2019157273A5 (enExample)
Kamal Potential effectiveness of sleep hygiene and relaxation Benson in improving the quality of sleep in patients with heart failure: Literature review
Crabb Sleep disorders in Parkinson's disease: the nursing role
US20230381168A1 (en) Adjunctive therapy for depression
Clayton et al. Combination therapy in fibromyalgia
CA2338327A1 (en) Use of moclobemide for treating pain and other diseases
Scharko et al. SSRI-induced sexual dysfunction in adolescents
Bean et al. 1099 Sleep Restriction Leads To Greater Next-day Anxiety: The Moderating Role Of Anxiety And Depression
Suzuki et al. Nocturnal Disturbances in Patients with Parkinson’s Disease